A review of current evidence for vilazodone in major depressive disorder
The DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.
Abstract
OBJECTIVES: This review is to inform clinicians of currently available data on vilazodone for treating patients with major depressive disorder (MDD), focusing on its differential action mechanism and extended clinical utility. METHODS: A data search was conducted in June 2012 using the PubMed/ MEDLINE/relevant clinical trial databases with the key terms "vilazodone" or "Viibryd." RESULTS: The efficacy, safety, and tolerability of vilazodone have been demonstrated in two pivotal 8-week, randomized, double-blinded, placebo-controlled studies. Certain pharmacological characteristics of vilazodone were observed, including early onset of action, fewer sexual side effects, the absence of known cardiac toxicity, and minimal effect on weight gain, that may provide potential clinical advantages compared with currently available antidepressants. However, such possibilities should be replicated and confirmed in more well-designed and adequately powered clinical trials. Vilazodone requires dose titration up to 2 weeks to reach a target dose of 40 mg/d due to high rate of gastrointestinal side effects. No direct comparative studies with other antidepressants are currently available to confirm the aforementioned potential clinical utility. CONCLUSION: Vilazodone is a newer antidepressant possessing different action mechanisms compared to currently available antidepressants but whether it has superiority to other class of antidepressants in terms of efficacy and safety should still warrant further evaluation through more well-controlled and direct comparison clinical trials.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Rush, A. J., Trivedi, M. H., Wisniewski, S. R., Nierenberg, A. A., Stewart, J. W., Warden, D., Niederehe, G., Thase, M. E., Lavori, P. W., Lebowitz, B. D., et al. (2006) · American Journal of Psychiatry · doi:10.1176/ajp.2006.163.11.1905 · Cited by 5,643
Medication Augmentation after the Failure of SSRIs for Depression
Trivedi, M. H., Fava, M., Wisniewski, S. R., Thase, M. E., Quitkin, F., Warden, D., Ritz, L., Nierenberg, A. A., Lebowitz, B. D., Biggs, M. M., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa052964 · Cited by 1,002 · cited 7×
“Buspirone, a 5-HT1A receptor partial agonist, which is considered an important augmenting agent, should be included when treating TRD (Trivedi et al. 2006; Nierenberg 2009).”
BackgroundInfluentialSSRI Antidepressant Medications: Adverse Effects and Tolerability
Ferguson, J. M. (2001) · The Primary Care Companion For CNS Disorders · doi:10.4088/pcc.v03n0105 · Cited by 669 · cited 1×
“A minimal weight gain seen in the pivotal trials and open-label long-term study is noteworthy (Administration 2012; Ferguson 2001) because weight gain is one of major leading causes of noncompliance during antidepressant treatment (Trivedi et al. 2007).”
BackgroundPrevalence of Sexual Dysfunction Among Newer Antidepressants
Clayton, A. H., Pradko, J. F., Croft, H. A., Montano, C. B., Leadbetter, R. A., Bolden-Watson, C., Bass, K. I., Donahue, R. M. J., Jamerson, B. D., & Metz, A. (2002) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v63n0414 · Cited by 542 · cited 3×
“However, favorable pharmacodynamic profi le of vilazodone regarding sexual dysfunction compared to other antidepressants may not be confi rmative yet since currently available clinical trials of vilazodone did not use SSRIs or SNRIs as active comparators and the individual items of sexual dysfunction scales did not sh…”
BackgroundMarcus, R. N., McQuade, R. D., Carson, W. H., Hennicken, D., Fava, M., Simon, J. S., Trivedi, M. H., Thase, M. E., & Berman, R. M. (2008) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e31816774f9 · Cited by 518
McEwen, B. S., Chattarji, S., Diamond, D. M., Jay, T. M., Reagan, L. P., Svenningsson, P., & Fuchs, E. (2010) · Molecular Psychiatry · doi:10.1038/mp.2009.80 · Cited by 406
Gartlehner, G., Hansen, R. A., Morgan, L. C., Thaler, K., Lux, L., Van Noord, M., Mager, U., Thieda, P., Gaynes, B. N., Wilkins, T., et al. (2011) · Annals of Internal Medicine · doi:10.7326/0003-4819-155-11-201112060-00009 · Cited by 355
Blier, P., Ward, H. E., Tremblay, P., Laberge, L., Hébert, C., & Bergeron, R. (2010) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2009.09020186 · Cited by 316 · cited 1×
“…rates, including treatment-resistant depression (TRD), may be improved by a polypharmacy strategy (Trivedi et al. 2006; Barowsky and Schwartz 2006; Blier et al. 2010; Rush et al. 2006), antidepressant-related prevailing adverse events (AEs) such as sexual dysfunction and weight gain are still…”
BackgroundThase, M. E., Corya, S. A., Osuntokun, O., Case, M., Henley, D. B., Sanger, T. M., Watson, S. B., & Dubé, S. (2007) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v68n0207 · Cited by 228
Bauer, M., Pretorius, H. W., Constant, E. L., Earley, W. R., Szamosi, J., & Brecher, M. (2009) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.08m04629 · Cited by 210
Cited by
Kennedy, S. H., Lam, R. W., McIntyre, R. S., Tourjman, S. V., Bhat, V., Blier, P., Hasnain, M., Jollant, F., Levitt, A. J., MacQueen, G. M., et al. (2016) · The Canadian Journal of Psychiatry · doi:10.1177/0706743716659417 · Cited by 1,181
Sanchez, C., Asin, K. E., & Artigas, F. (2015) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2014.07.001 · Cited by 547
Pehrson, A. L., & Sanchez, C. (2014) · CNS Spectrums · doi:10.1017/s1092852913000540 · Cited by 161
Wang, S.-M., Han, C., Lee, S.-J., Patkar, A. A., Masand, P. S., & Pae, C.-U. (2015) · Psychiatry Investigation · doi:10.4306/pi.2015.12.2.155 · Cited by 36
Self-citation
Metadata
- Authors
- Wang, S.-M., Han, C., Lee, S.-J., Patkar, A. A., Masand, P. S., & Pae, C.-U.
- Venue
- International Journal of Psychiatry in Clinical Practice
- Publisher
- Informa UK Limited
- Published
- 2013-05-29
- Volume
- 17
- Issue
- 3
- Pages
- 160-169
- ISSN
- 1365-1501 (ISSN-L)
- 1471-1788
- OpenAlex
- W1971355892
- Cited by
- 37
- References
- 12
- FWCI
- 3.69
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: A review of current evidence for vilazodone in major depressive disorder. https://app.cochat.ai/papers/10.3109/13651501.2013.794245
- The paper
- Wang, S.-M., Han, C., Lee, S.-J., Patkar, A. A., Masand, P. S., & Pae, C.-U. (2013). A review of current evidence for vilazodone in major depressive disorder. International Journal of Psychiatry in Clinical Practice. https://doi.org/10.3109/13651501.2013.794245
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.